NCT Number: NCT02498236
Target Engagement for Oxytocin: Dose Ranging Study
This study will evaluate the effect of 8 doses of intranasal oxytocin or placebo on two proposed measures of target engagement in brain. The targets are (1) the suppression of a particular wave form (mu) on the electroencephalogram (EEG) while subjects observe a socially relevant form of motion and (2) pupil dilation will subjects identify faces showing different emotions.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
Subjects with schizophrenia spectrum disorders will be randomly assigned to one of 8 doses of oxytocin. After screening and informed consent subjects will receive either their assigned dose or a placebo. Thirty minutes following the drug administration patients will be evaluated on the EEG and pupillometry tasks followed by two tests that evaluate social salience. One week later subjects will have a second challenge in the alternative (drug or placebo) condition.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Able to cooperate with study procedures
Exclusion criteria
- Serious medical condition or substance use
- Pregnancy
Treatment and study plan
Primary outcomes
-
Mu Suppression on EEG
Time frame: Baseline, 1 Week
This primary outcome measure is mu suppression recorded during a biological motion task. In this task, participants view point-light walker (PLW) animations of a human; the PLWs were either male or female, happy or sad, or walking towards or away from the viewer. In addition to the humans, there was a control condition which consisted of a circle moving either left or right. In separate blocks, participants had to identify either the gender, the emotion, or intention (i.e., direction) of the walker, or the direction of the circle, while their EEG was recorded. The primary measure was mu activity (8-12 Hz) recorded over 3 central electrodes. Mu suppression was calculated as the log10 transformed ratio of mu power to one of the three human conditions compared to the circle: log10(human/circle). A negative value indicates suppression of mu activity to human walkers vs. circles. We are presenting the mean (SD) of this suppression ratio collapsed over the 3 human conditions.
-
Pupil Dilation While Observing Faces
Time frame: Baseline, 1 Week
This primary outcome measure is pupil size recorded during a facial affect identification task. In this task, participants view faces portraying happy, afraid, or neutral faces; scrambled images of the faces were also shown. There were 64 trials: 16 trials per each image type. The primary measure was the difference in pupil size averaged over the happy and fearful faces from the scrambled face condition. A positive value indicates greater pupil dilation relative to the scrambled face; a negative value indicates greater pupil constriction relative to the scrambled face.
Baseline was defined as the median pupil width 1 second prior to stimulus onset. Pupil sizes during each trial were baseline-corrected by dividing them by baseline median width. Resulting pupil size timecourses were averaged within-subject for each type of stimulus (happy, afraid, neutral, scrambled). The primary dependent variable was computed by taking the average of the change in pupil size between 1 and 3 s.
Sponsors and collaborators
Lead sponsor
University of California, Los Angeles
Other
Registry information
Official study title
Target Engagement for Oxytocin: Response to 8 Doses
Acronym: R21Dose
Important dates
- Study start
- 2015
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Jul 15, 2015
- Registry last updated
- Jan 31, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Relative Bioavailability of LY03010 Compared to Listed Drug
NCT04922593
Antipsychotic Agents, Central Nervous System Depressants
Garden Grove, California, United States
View Trial DetailsCost-utility Study of Cognitive-behavioral Management of Auditory Hallucinations in Schizophrenic Disorder
NCT07134816
Auditory Hallucinations, Hallucinations
Montpellier, Occitanie, France
View Trial DetailsTele-group Cognitive Behavioural Family Intervention for People With Schizophrenia and Their Families (Feasibility tgCBFI)
NCT05808244
Mental Disorders, Psychosis
Kowloon, Hong Kong
View Trial DetailsPersonalized and Scalable Cognitive Remediation Approaches
NCT01945333
Mental Disorders, Psychotic Disorders
Brooklyn, New York, United States
View Trial Details